By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metabolon said today it is using its metabolomic technology to discover therapeutic targets and biomarkers under a collaboration with Takeda Pharmaceutical.

Under the multi-year deal, Metabolon will apply its analytical platform and software to discover and validate targets and to identify novel pharmacodynamic biomarkers for translation into the clinic.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.